Skip to content
DE

Celiac blood tests: making sense of results and reference ranges

Clinical review pending

What tTG-IgA, EMA, and total IgA mean, why laboratory cutoffs differ, and when celiac blood test results need further investigation.

A capped transparent sample tube contains a curled coral ribbon.

A positive celiac blood test can point to an immune response involving gluten, but it does not establish the diagnosis on its own in every situation. The test used, the laboratory’s upper limit of normal, how much gluten you are currently eating, and your total IgA level all matter. That is why the same number can mean different things on two lab reports.

What a celiac blood test measures

The usual first antibody test is tTG-IgA. It measures immunoglobulin A antibodies against tissue transglutaminase, an enzyme in your own body that is involved in the immune response in celiac disease. In genetically susceptible people, gluten from wheat, barley, and rye can trigger a response that damages the lining of the small intestine. Reviews of diagnostic testing and celiac disease explain this connection.

Some assays report tTG-IgA in U/mL. One example defines results below 4 U/mL as negative, 4–10 U/mL as weakly positive, and above 10 U/mL as positive. Other assays use different thresholds, such as 15 or 30 U/mL. The tTG-IgA patient information and diagnostic guideline illustrate why you need the reference range printed on your own report. In the example above, “weakly positive” is the laboratory’s actual category; it should not simply be relabeled negative or borderline.

Other tests include endomysial antibodies, or EMA; antibodies against deamidated gliadin peptides, or DGP; and total IgA. They answer different questions. Total IgA is not another positive-or-negative celiac antibody test. It helps identify IgA deficiency, which can make an IgA-based antibody result misleading. Diagnostic guidance explains how these tests fit together; the American College of Gastroenterology published an updated guideline in 2023.

Reference ranges: why 10 times the upper limit matters

A tTG-IgA result at least 10 times the upper limit of normal is markedly elevated. “10 × ULN” refers to the upper limit for that particular assay, making it more useful than one supposedly universal number. Under specific conditions, a result this high can be part of a diagnosis without an intestinal biopsy. The requirements vary by age, guideline, and clinical circumstances and need specialist assessment.

For example, the 2020 European pediatric guideline permits a no-biopsy diagnosis in selected children with tTG-IgA at least 10 × ULN and positive EMA-IgA in a second blood sample, with the family’s agreement. US adult guidance generally still calls for a biopsy to confirm the diagnosis. European adult guidance published in 2025 also allows a conditional no-biopsy pathway for selected adults younger than 45. A high result is therefore a reason to discuss the appropriate pathway, not to assume that all further testing is unnecessary.

The table below gives examples from particular assays. It is not a universal reference chart and does not replace the ranges supplied by your laboratory.

Marker Negative or within the expected range Weakly positive Positive
tTG-IgA Below 4 U/mL 4–10 U/mL Above 10 U/mL
DGP-IgA/IgG Below 20 units 20–30 units Above 30 units
EMA-IgA Not detected Not usually reported this way Detected
Total IgA Within the age- and laboratory-specific reference range This classification does not apply This classification does not apply

These numerical examples come from the Mayo Clinic Laboratories catalogs for tTG-IgA and DGP-IgA/IgG. The tTG-IgA overview and European guideline provide further context. A gluten-challenge study registration describes a research protocol, not a general recommendation for laboratory thresholds.

A total IgA level below 7 mg/dL is commonly part of the definition of selective IgA deficiency, although age and other diagnostic conditions also matter. In that situation, tTG-IgA can be negative despite celiac disease. The literature on IgA deficiency helps explain why IgG-based tests may be useful instead.

Early or potential disease can involve antibodies without typical intestinal damage, as described in a study of potential celiac disease. Separately, reducing gluten before testing can lower antibody levels and make the workup less reliable. Do not independently switch to a gluten-free diet before diagnostic testing is complete. If you have already avoided gluten for a long time, any gluten challenge should be planned with your clinician. A commonly mentioned period such as at least 6 weeks is not sufficient for every situation: the amount of gluten, duration, and tolerability all need consideration.

What a positive tTG-IgA result means

A clearly elevated result makes celiac disease more likely. Across groups of patients, higher antibody levels are often associated with more intestinal damage, but the relationship is not identical in every person. A gluten-challenge study and a study comparing antibody levels with intestinal biopsy findings show why blood results, symptoms, and, when appropriate, a biopsy need to be interpreted together.

The number does not reliably tell you how ill someone feels. Some people have high antibody levels with few symptoms; others have substantial symptoms with lower levels. Coexisting autoimmune conditions can also complicate interpretation.

The HLA variants DQ2 and DQ8 are present in most people with celiac disease, but they are also common in people who do not have it. A positive genetic result therefore cannot establish the diagnosis. A positive antibody test is a reason for gastroenterology follow-up before permanently removing gluten and making subsequent investigations harder to interpret.

Negative results and possible false negatives

When the right tests are performed under suitable conditions, a negative result lowers the likelihood of celiac disease. It does not rule it out in every case. Eating too little gluten before testing is one important reason for a false negative.

About 2–3% of people with celiac disease have IgA deficiency. An IgA-based test can then miss the antibody response. Research on antibody testing and the diagnostic guideline support assessing tTG-IgA alongside total IgA.

Early disease and immunosuppressive medications can also affect the antibody response. Antibody levels often fall after a gluten-free diet, as described in research on follow-up testing. If suspicion remains high, further evaluation is more useful than interpreting one negative result in isolation. These antibody tests also neither confirm nor exclude non-celiac wheat sensitivity.

What happens during testing

Celiac antibody testing requires a blood sample. You generally do not need to fast for these antibodies alone, although other tests ordered at the same time may have different instructions. The time of day matters less than gluten intake and choosing the appropriate tests.

Many laboratories use immunological methods such as ELISA. Results may be available in a few business days; an estimate such as 1–3 days depends on the laboratory and should be confirmed when the test is ordered. Not everyone needs every available antibody test. tTG-IgA and total IgA are often the starting point, with EMA or IgG-based tests added to answer particular questions.

Whether an unclear result needs repeating depends on the clinical situation. After a confirmed diagnosis, antibody trends help assess the response to a gluten-free diet. Normal results do not, however, prove that the intestinal lining has fully healed.

What can change the results

Gluten intake is an important influence. Even small amounts can matter in celiac disease, as a controlled gluten-tolerance study demonstrated. Still, a single antibody result cannot reliably tell you how much gluten someone has eaten.

With a consistently gluten-free diet, levels often fall substantially within 6–12 months. Full normalization can take longer, sometimes years. A review of disease management and research on the reliability of follow-up testing describe this variation. Accidental exposure through ingredients or shared kitchen surfaces can play a role, but it is not the only explanation for unexpected results.

Type 1 diabetes and autoimmune thyroid disease occur more often in people with celiac disease. A study of thyroid disease risk examines one of these associations. Medications, age, genetic susceptibility, and the assay also influence the overall interpretation. None provides a simple age-based correction factor for an individual result.

Other lab results that may be relevant

C-reactive protein, or CRP, and the erythrocyte sedimentation rate are not reliably elevated in celiac disease. Normal general inflammation markers therefore do not exclude it. Research on sugar absorption tests examines different aspects of intestinal function from those measured by celiac-specific antibody tests.

Untreated celiac disease can be accompanied by iron deficiency or anemia and low vitamin D, vitamin B12, or folate. A review of nutrient deficiencies explains why additional tests should be selected according to symptoms and findings. Liver enzymes such as ALT and AST can also be elevated and may improve with treatment, as discussed in the literature on celiac-related liver changes. Other causes of elevated liver enzymes still need consideration.

If there are signs of thyroid disease, TSH is often the first test, followed by others as indicated. A complete thyroid or nutrient panel is not automatically necessary in every situation.

Why a targeted celiac evaluation matters

Celiac disease affects roughly 1% of the population, with estimates varying by population and testing method. In a 2012 US population study, the estimate was 0.71%; 29 of the 35 participants identified with celiac disease did not know they had it. That roughly 83% figure describes this particular study, not the proportion currently undiagnosed everywhere. A separate study of diagnostic delays examined why diagnosis can take a long time. Symptoms may be attributed to other conditions, and some people have few digestive symptoms at all.

A diagnosis makes targeted treatment possible, including assessment for consequences such as nutrient deficiencies or low bone density. A disease overview discusses broader complications, including neurological and reproductive problems. A large cohort study specifically examines cancer risk, including uncommon malignancies. An antibody result alone cannot reveal an individual’s long-term risk.

Among first-degree relatives, a meta-analysis found a pooled prevalence of 7.5%. It was approximately 1 in 7 among sisters and 1 in 8 among daughters, rather than 14% for all siblings or all female relatives. Research in children from high-risk families further supports individualized screening discussions. Whether and when to repeat testing depends partly on age, symptoms, and previous results.

Frequently asked questions

What counts as a positive celiac test?

An antibody result above the cutoff for the assay used. Some laboratories use a tTG-IgA threshold around 15 U/mL; others use different values. A result at least 10 times the upper limit of normal is markedly elevated. The next diagnostic steps depend on age, other findings, and the applicable guideline.

Which four markers are often mentioned?

tTG-IgA, total IgA, EMA, and DGP antibodies. Total IgA helps establish whether an IgA-based test is reliable. EMA and DGP are added selectively; they are not equally useful or necessary for everyone.

What does a weakly positive or borderline result mean?

It can fit early or potential celiac disease, but there can be other explanations. “Borderline” is a category defined by the particular laboratory. The entire range below 10 times the upper limit of normal is not simply borderline. Additional testing may be needed.

What is potential celiac disease?

This describes compatible antibodies without typical villous atrophy on a small-intestinal biopsy, such as a Marsh 0/I finding. It does not inevitably progress to established intestinal damage in every person. Follow-up should be guided by a gastroenterologist.

Why can a test be negative despite celiac disease?

Possible reasons include already eating little or no gluten, IgA deficiency, early disease, or a suppressed immune response. After prolonged gluten avoidance, a gluten challenge needs an individual plan. A blanket 6-week rule does not resolve every diagnostic situation.

How does a gluten-free diet affect the results?

Antibodies often fall considerably within 6–12 months, but they can stay elevated longer. Persistently or newly elevated results can indicate gluten exposure. Conversely, normal results do not guarantee complete healing of the intestinal lining.

Which other results can be abnormal?

Examples include a blood count and iron studies, vitamin D, vitamin B12, folate, ALT, and AST. Testing should reflect symptoms, nutritional status, and progress over time.

How often are antibody levels checked?

After a confirmed diagnosis, the AGA clinical practice update recommends follow-up serology at 6 and 12 months, then annually. The schedule can be adjusted to the clinical course and treatment. An unclear initial result needs its own diagnostic plan rather than a routine long-term monitoring schedule.

Sources

  • Chou R, Bougatsos C, Blazina I, Mackey K, Grusing S, Selph S (2017). Screening for Celiac Disease: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 317(12), 1258-1268. https://doi.org/10.1001/jama.2016.10395 PubMed

  • Chow MA, Lebwohl B, Reilly NR, Green PH (2012). Immunoglobulin A deficiency in celiac disease. Journal of clinical gastroenterology, 46(10), 850-4. https://doi.org/10.1097/MCG.0b013e31824b2277 PubMed

  • Husby S, Koletzko S, Korponay-Szabó I, Kurppa K, Mearin ML, Ribes-Koninckx C, Shamir R, Troncone R, Auricchio R, Castillejo G, Christensen R, Dolinsek J, Gillett P, Hróbjartsson A, Koltai T, Maki M, Nielsen SM, Popp A, Størdal K, … Wessels M (2020). European Society Paediatric Gastroenterology, Hepatology and Nutrition Guidelines for Diagnosing Coeliac Disease 2020. Journal of pediatric gastroenterology and nutrition, 70(1), 141-156. https://doi.org/10.1097/MPG.0000000000002497 PubMed

  • Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA, American College of Gastroenterology (2013). ACG clinical guidelines: diagnosis and management of celiac disease. The American journal of gastroenterology, 108(5), 656-76; quiz 677. https://doi.org/10.1038/ajg.2013.79 PubMed

  • Lebwohl B, Sanders DS, Green PHR (2018). Coeliac disease. Lancet (London, England), 391(10115), 70-81. https://doi.org/10.1016/S0140-6736(17)31796-8 PubMed

  • Wang M, Lu JJ, Li T, Ma CT, Li ZQ, Abudurexiti A, Hui WJ, Wang C, Sun ZZ, Gao F (2023). [Association between anti-tissue transglutaminase antibody titers and duodenal histopathology among adults with celiac disease]. Zhonghua nei ke za zhi, 62(2), 188-192. https://doi.org/10.3760/cma.j.cn112138-20220220-00127 PubMed

  • Volta U, Caio G, Giancola F, Rhoden KJ, Ruggeri E, Boschetti E, Stanghellini V, De Giorgio R (2016). Features and Progression of Potential Celiac Disease in Adults. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 14(5), 686-93.e1. https://doi.org/10.1016/j.cgh.2015.10.024 PubMed

  • Leffler D, Schuppan D, Pallav K, Najarian R, Goldsmith JD, Hansen J, Kabbani T, Dennis M, Kelly CP (2013). Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut, 62(7), 996-1004. https://doi.org/10.1136/gutjnl-2012-302196 PubMed

  • Jain R, Kumar P, Kapoor S, Basu S, Lomash A, Rohatgi S (2019). Reliability of coeliac serology in monitoring dietary adherence in children with coeliac disease on a gluten-free diet. Tropical doctor, 49(3), 192-196. https://doi.org/10.1177/0049475519835732 PubMed

  • Catassi C, Fabiani E, Iacono G, D’Agate C, Francavilla R, Biagi F, Volta U, Accomando S, Picarelli A, De Vitis I, Pianelli G, Gesuita R, Carle F, Mandolesi A, Bearzi I, Fasano A (2007). A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease. The American journal of clinical nutrition, 85(1), 160-6. https://doi.org/10.1093/ajcn/85.1.160 PubMed

  • Glissen Brown JR, Singh P (2019). Coeliac disease. Paediatrics and international child health, 39(1), 23-31. https://doi.org/10.1080/20469047.2018.1504431 PubMed

  • Elfström P, Montgomery SM, Kämpe O, Ekbom A, Ludvigsson JF (2008). Risk of thyroid disease in individuals with celiac disease. The Journal of clinical endocrinology and metabolism, 93(10), 3915-21. https://doi.org/10.1210/jc.2008-0798 PubMed

  • Holtz LR, Hoffmann J, Linneman L, He M, Smyrk TC, Liu TC, Shaikh N, Rodriguez C, Dyer RB, Singh RJ, Faubion WA (2022). Rhamnose Is Superior to Mannitol as a Monosaccharide in the Dual Sugar Absorption Test: A Prospective Randomized Study in Children With Treatment-Naïve Celiac Disease. Frontiers in pediatrics, 10, 874116. https://doi.org/10.3389/fped.2022.874116 PubMed

  • Caruso R, Pallone F, Stasi E, Romeo S, Monteleone G (2013). Appropriate nutrient supplementation in celiac disease. Annals of medicine, 45(8), 522-31. https://doi.org/10.3109/07853890.2013.849383 PubMed

  • Marciano F, Savoia M, Vajro P (2016). Celiac disease-related hepatic injury: Insights into associated conditions and underlying pathomechanisms. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 48(2), 112-9. https://doi.org/10.1016/j.dld.2015.11.013 PubMed

  • Rubio-Tapia A, Ludvigsson JF, Brantner TL, Murray JA, Everhart JE (2012). The prevalence of celiac disease in the United States. The American journal of gastroenterology, 107(10), 1538-44; quiz 1537, 1545. https://doi.org/10.1038/ajg.2012.219 PubMed

  • Fuchs V, Kurppa K, Huhtala H, Collin P, Mäki M, Kaukinen K (2014). Factors associated with long diagnostic delay in celiac disease. Scandinavian journal of gastroenterology, 49(11), 1304-10. https://doi.org/10.3109/00365521.2014.923502 PubMed

  • Lebwohl B, Green PHR, Emilsson L, Mårild K, Söderling J, Roelstraete B, Ludvigsson JF (2022). Cancer Risk in 47,241 Individuals With Celiac Disease: A Nationwide Cohort Study. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 20(2), e111-e131. https://doi.org/10.1016/j.cgh.2021.05.034 PubMed

  • Singh P, Arora S, Lal S, Strand TA, Makharia GK (2015). Risk of Celiac Disease in the First- and Second-Degree Relatives of Patients With Celiac Disease: A Systematic Review and Meta-Analysis. The American journal of gastroenterology, 110(11), 1539-48. https://doi.org/10.1038/ajg.2015.296 PubMed

  • Meijer CR, Auricchio R, Putter H, Castillejo G, Crespo P, Gyimesi J, Hartman C, Kolacek S, Koletzko S, Korponay-Szabo I, Ojinaga EM, Polanco I, Ribes-Koninckx C, Shamir R, Szajewska H, Troncone R, Villanacci V, Werkstetter K, Mearin ML (2022). Prediction Models for Celiac Disease Development in Children From High-Risk Families: Data From the PreventCD Cohort. Gastroenterology, 163(2), 426-436. https://doi.org/10.1053/j.gastro.2022.04.030 PubMed

  • Cleveland Clinic. (n.d.). tTG-IgA Test (Tissue Transglutaminase IgA Test). https://my.clevelandclinic.org/health/diagnostics/ttg-iga-test

  • ClinicalTrials.gov. (n.d.). Circulating Markers of Celiac Disease Activity During Gluten Challenge - a Pilot Study (NCT00931892). https://clinicaltrials.gov/study/NCT00931892

  • Azzi L, Croveri F, Vinci R, Maurino V, Boggio A, Mantegazza D, Farronato D, Tagliabue A, Silvestre-Rangil J, Tettamanti L (2017). Oral manifestations of selective IgA-deficiency: review and case-report. Journal of biological regulators and homeostatic agents, 31(2 Suppl 1), 113-117. PubMed

  • Mayo Clinic Laboratories. Tissue Transglutaminase Antibody, IgA, Serum. https://www.mayocliniclabs.com/test-catalog/Overview/82587

  • Mayo Clinic Laboratories. Gliadin (Deamidated) Antibodies Evaluation, IgG and IgA, Serum. https://www.mayocliniclabs.com/test-catalog/overview/89031/gliadin-deamidated-antibodies-evaluation-igg-and-iga-serum

  • Rubio-Tapia A, Hill ID, Semrad C, Kelly CP, Greer KB, Limketkai BN, Lebwohl B (2023). American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. https://doi.org/10.14309/ajg.0000000000002075 PubMed

  • Al-Toma A et al. (2025). European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach. https://doi.org/10.1002/ueg2.70119 Full text

  • Husby S, Murray JA, Katzka DA (2019). AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review. https://doi.org/10.1053/j.gastro.2018.12.010 PubMed